EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study

Jonathan L Ciofani iD, Daniel Han, Karan Rao, Dipender Gill iD, Benjamin Woolf iD, Kazem Rahimi, Usaid K Allahwala, Ravinay Bhindi

European Heart Journal - Cardiovascular Pharmacotherapy · 2025

DOI: 10.1093/ehjcvp/pvae092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2025. Verfasst von Jonathan L Ciofani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Medical School, The University of Sydney, Camperdown, NSW 2006, Australia. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Cholesterol, LDL, Dyslipidemias, Hypolipidemic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: British Heart Foundation, UKRI, Heart Research Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Large observational and Mendelian randomization (MR) studies have demonstrated a strong association between both elevated LDL cholesterol (LDL-c) and triglycerides (TG) with risk of aortic stenosis (AS), although randomized trials showed no benefit of statins for AS. It consequently remains uncertain whether lipid-lowering therapies have a role to prevent or treat AS. We used a drug-target MR approach to investigate the genetically predicted effect of lipid-lowering therapies on risk of AS. Methods and results We collected summary statistics for LDL-c, TG, and AS from genome-wide association studies (GWAS) including 1 320 016, 1 253 277, and 412 181 European participants from the Global Lipids Genetics Consortium and FinnGen study, respectively. We identified genetic proxies for PCSK9 inhibitors, statins, bempedoic acid, and ezetimibe as single nucleotide polymorphisms in or within 200 kb of the target genes (PCSK9, HMGCR, ACLY, and NPC1L1, respectively), which were also significantly associated with LDL-c at P < 5 × 10−8. We used a similar approach to identify genetic proxies for the TG-lowering agents fenofibrates, APOC3 inhibitors, and ANGPTL3 inhibitors using the target genes PPARA, APOC3, and ANGPTL3, respectively. Inverse variance-weighted was the primary analysis method. Sensitivity analyses included weighted median, weighted mode, and MR-Egger, followed by the outlier-exclusion approaches MR-PRESSO and Cook's distance. We also performed multivariable analyses to evaluate whether the predicted effect of PCSK9 inhibition may be mediated by lipoprotein(a). We performed replication and negative control analyses using GWAS of AS and height including 653 867 and 408 112 participants, respectively. Genetically proxied PCSK9 inhibition was significantly associated with reduced AS risk (odds ratio [OR] 0.61, 95% confidence interval [CI] 0.52–0.72, P < 0.0001) on main, replication, and all sensitivity analyses. Genetically proxied ezetimibe (OR 0.49, 95% CI 0.31–0.78, P = 0.003), bempedoic acid (OR 0.0054, 95% CI 0.0002–0.12, P = 0.0009), and statins (OR 0.61, 95% CI 0.46–0.81, P = 0.0006) were similarly associated with reduced AS risk, although the latter were not significant on replication analyses. Amongst the TG-lowering agents, genetically proxied APOC3 inhibition was associated with reduced AS risk (OR 0.78, 95% CI 0.70–0.88, P < 0.0001), but fenofibrate (OR 0.64, 95% CI 0.09–4.53, P = 0.65) and ANGPTL3 inhibitors (OR 1.05, 95% CI 0.77–1.43, P = 0.74) were not.

Conclusions

Genetically proxied lipid-lowering therapies are significantly associated with reduced risk of AS. Early initiation and sustained administration of lipid-lowering therapies may prevent AS progression and warrants further research in the clinical trial setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve StenosisCholesterol, LDLDyslipidemiasHypolipidemic AgentsTriglyceridesPharmacogenomic VariantsAnticholesteremic AgentsHumansMendelian Randomization AnalysisRisk FactorsGenome-Wide Association StudyPolymorphism, Single NucleotideTreatment OutcomeBiomarkersRisk AssessmentPhenotypeGenetic Predisposition to DiseasePCSK9 InhibitorsMaleProprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase Inhibitors

Stichwörter der Autor:innen

Aortic stenosisEpidemiologyGenetic epidemiologyLipid-lowering therapyMendelian randomizationValvular heart disease

Substanzen

Cholesterol, LDLBiomarkersHypolipidemic AgentsTriglyceridesPCSK9 protein, humanPCSK9 InhibitorsAnticholesteremic AgentsProprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Sydney Medical School, The University of Sydney, Camperdown, NSW 2006, Australia.
  • Department of Cardiology, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065, Australia.
  • Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, Exhibition Rd, South Kensington, London SW7 2AZ, UK.
  • School of Mathematics and Statistics, University of New South Wales, Sydney 2052, Australia.
  • MRC Biostatistics Unit, University of Cambridge, Cambridge CB2 1TN, UK.
  • MRC Integrative Epidemiology Unit, University of Bristol, Bristol BS8 1QU, UK.

ORCID-Profile: Jonathan L Ciofani, Dipender Gill, Benjamin Woolf

Förderung

  • British Heart Foundation
  • UKRI
  • Heart Research Australia

Zitieren

APA

Ciofani, J. L., Han, D., Rao, K., Gill, D., Woolf, B., Rahimi, K., Allahwala, U. K., & Bhindi, R. (2025). Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae092

Vancouver

Ciofani JL, Han D, Rao K, Gill D, Woolf B, Rahimi K, et al. Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study. European Heart Journal - Cardiovascular Pharmacotherapy. 2025. doi:10.1093/ehjcvp/pvae092

BibTeX
@article{Ciofani2025,
  author = {Ciofani, Jonathan L and Han, Daniel and Rao, Karan and Gill, Dipender and Woolf, Benjamin and Rahimi, Kazem and Allahwala, Usaid K and Bhindi, Ravinay},
  title = {Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2025},
  doi = {10.1093/ehjcvp/pvae092}
}
Kostenlos starten →